Redo TAVR: Supra-Annular, Intra-Annular Valves Linked to Comparable Outcomes

Why It Matters

The findings suggest that valve type selection for redo TAVR can be flexible, expanding treatment options for patients with failing transcatheter valves and guiding procedural planning.

Key Takeaways

• Redo TAVR shows similar 1‑year mortality across valve configurations.
• Structural valve deterioration caused 78% of repeat procedures.
• IAV‑IAV group had lowest survival and higher gradients.
• Single antiplatelet therapy associated with improved one‑year survival.

Pulse Analysis

Transcatheter aortic valve replacement has become the preferred therapy for many patients with severe aortic stenosis, and the growing volume of first‑time procedures inevitably creates a cohort that will require repeat interventions. Redo TAVR, or TAVR‑in‑TAVR, offers a less invasive alternative to surgical valve replacement, but clinicians have questioned whether the type of valve implanted first—supra‑annular versus intra‑annular—might affect outcomes after a second device is placed. The PANDORA registry, encompassing 172 redo cases from 2011 to 2024, provides the most comprehensive data set to date, showing that overall one‑year mortality and heart‑failure rates are statistically similar across all valve‑configuration groups.

The analysis highlights that structural valve deterioration drives the majority (78%) of redo procedures, underscoring the importance of long‑term durability in device design. While the intra‑annular‑to‑intra‑annular (IAV‑IAV) subgroup exhibited the lowest survival (76.1%) and the highest residual transvalvular gradients, these differences did not reach statistical significance, suggesting that procedural success may hinge more on patient‑specific factors than on valve geometry alone. Notably, the study found that men and patients with chronic kidney disease faced higher mortality risk, reinforcing the need for meticulous risk stratification before repeat interventions.

Antiplatelet strategy emerged as a modifiable factor: single antiplatelet therapy correlated with improved one‑year survival, aligning with emerging evidence that a simplified regimen can reduce bleeding without raising thrombotic risk. However, the authors caution that this association may reflect patient selection bias. The results encourage clinicians to adopt a case‑by‑case approach, leveraging thorough imaging and heart‑team discussions to optimize valve choice and medical therapy. As the market for redo TAVR expands, manufacturers may prioritize designs that facilitate seamless valve‑in‑valve implantation, while ongoing trials will be essential to confirm the durability and safety of various valve combinations.